|
|
Volumn 2, Issue 11, 2002, Pages 1613-1618
|
|
Implications of the new FDA/CDER immunotoxicology guidance for drugs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CYTOKINE;
IMMUNOGLOBULIN E;
IMMUNOSUPPRESSIVE AGENT;
PENICILLIN G;
IMMUNOLOGICAL ADJUVANT;
ANAPHYLAXIS;
ARTICLE;
BONE MARROW SUPPRESSION;
CARCINOGENICITY;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG RESEARCH;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNE FUNCTION TEST;
IMMUNE SYSTEM;
IMMUNOASSAY;
IMMUNOGENICITY;
IMMUNOSTIMULATION;
IMMUNOSUPPRESSIVE TREATMENT;
IMMUNOTOXICITY;
INFECTION;
NONHUMAN;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
SIDE EFFECT;
SKIN ALLERGY;
IMMUNOLOGY;
STANDARD;
TOXICOLOGY;
UNITED STATES;
ADJUVANTS, IMMUNOLOGIC;
ALLERGY AND IMMUNOLOGY;
DRUG HYPERSENSITIVITY;
IMMUNOSUPPRESSIVE AGENTS;
TOXICOLOGY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0036801073
PISSN: 15675769
EISSN: None
Source Type: Journal
DOI: 10.1016/S1567-5769(02)00061-9 Document Type: Article |
|
Times cited : (36)
|
|
References (0)
|
